Cargando…
Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk
Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a”boxed” warning regard...
Autores principales: | Feaver, Ryan E., Bowers, M. Scott, Cole, Banumathi K., Hoang, Steve, Lawson, Mark J., Taylor, Justin, LaMoreaux, Brian D., Zhao, Lin, Henke, Brad R., Johns, Brian A., Nyborg, Andrew C., Wamhoff, Brian R., Figler, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10490929/ https://www.ncbi.nlm.nih.gov/pubmed/37682977 http://dx.doi.org/10.1371/journal.pone.0291330 |
Ejemplares similares
-
Exposure of Induced Pluripotent Stem Cell‐Derived Vascular Endothelial and Smooth Muscle Cells in Coculture to Hemodynamics Induces Primary Vascular Cell‐Like Phenotypes
por: Collado, Maria S., et al.
Publicado: (2017) -
Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
por: Saito, Hirotaka, et al.
Publicado: (2021) -
The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease
por: Higgins, Peter, et al.
Publicado: (2009) -
Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease
por: Hoang, Stephen A., et al.
Publicado: (2019) -
Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta‐analysis
por: Zhang, Jufen, et al.
Publicado: (2016)